{"id":449846,"date":"2021-03-03T12:15:40","date_gmt":"2021-03-03T17:15:40","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=449846"},"modified":"2021-03-03T12:15:40","modified_gmt":"2021-03-03T17:15:40","slug":"geneos-therapeutics-secures-12-million-in-series-a1-financing-to-advance-personalized-cancer-immunotherapy-programs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/geneos-therapeutics-secures-12-million-in-series-a1-financing-to-advance-personalized-cancer-immunotherapy-programs\/","title":{"rendered":"Geneos Therapeutics Secures $12 Million in Series A1 Financing to Advance Personalized Cancer Immunotherapy Programs"},"content":{"rendered":"
\n

Geneos expands its lead program for treating patients with advanced hepatocellular carcinoma<\/h2>\n

Geneos adds to its leadership team<\/h2>\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n PLYMOUTH MEETING, Pa.<\/span>, March 3, 2021<\/span> \/PRNewswire\/ — Geneos Therapeutics, a clinical stage company focused on the development of tumor neoantigen targeted personalized immunotherapies for cancer, announced today that it has closed its Series A1 round, raising $12 million<\/span> in financing. The financing was led by Korea Investment Partners (KIP) \u2013 Global Bio Fund with strong participation from all existing Series A investors including, notably, Sant\u00e9 Ventures and Inovio Pharmaceuticals, Inc. (NASDAQ: INO). The new investment follows the previously announced initial financing of $10.5 million<\/span> in February 2019<\/span>. In conjunction with the financing, Mr. Sangwoo Lee<\/span>, Managing Director Korea Investment Partners \u2013 USA<\/span> Inc. joined Geneos’ Board of Directors.<\/p>\n

“Geneos has made great strides in advancing the novel and differentiated GT-EPIC\u2122 platform for personalized cancer treatments,” commented Mr. Lee. “KIP is pleased to join the company’s investment syndicate and help support the team with its development plans.” <\/p>\n

The proceeds will be used for the expansion of the company’s GT-30 Phase Ib\/IIa clinical trial evaluating its personalized neoantigen-targeting vaccine, GNOS-PV02, for treating patients with advanced hepatocellular carcinoma (HCC), a type of liver cancer. GNOS-PV02, which is based on Geneos’ proprietary GT-EPIC\u2122 platform, is a tumor-specific DNA plasmid product designed and manufactured for each patient based on their unique tumor mutations’ (neoantigens), identified by sequencing each patient’s tumor.\u00a0 In the trial, GNOS-PV02 is combined with a DNA plasmid encoded cytokine immunomodulator IL-12 (INO-9012) and PD-1 checkpoint inhibitor (pembrolizumab). Geneos has amended the trial protocol to expand enrollment from the initial 12 patients to 24 patients.\u00a0 <\/p>\n

“The Series A1 financing demonstrates our investors’ confidence in the GT-EPIC platform to design and manufacture patient-specific personalized cancer vaccines,” said Dr. Niranjan Y. Sardesai<\/span>, Founder and Chief Executive Officer of Geneos Therapeutics. “Over the past two years we have demonstrated feasibility of the approach as a treatment modality \u2013 notably, the rapid biopsy to treatment turnaround time, which is so crucial when treating advanced cancer patients. This financing will allow us to expand our GT-30 clinical trial to a larger number of patients which we estimate will be sufficient to demonstrate efficacy in the 2nd<\/sup> line setting.”<\/p>\n

The company also announced the expansion of its management team with the addition of leadership team members who collectively bring decades of biopharmaceutical development expertise across early and late-stage clinical programs and pharma\/biotech partnering. Joining the company’s leadership team are:<\/p>\n